![]() © American Association for Clinical Chemistry 2021. POCT Glucose Accu-Chek Inform II Procedure OBJECTIVE This procedure describes the appropriate use of the Roche Accu-Chek Inform II glucose monitoring system for the quantitative measurement of glucose in capillary, venous or arterial whole blood. The ACCU-CHEK Inform II system demonstrated clinically acceptable performance against the PCA-HK reference method for blood glucose monitoring in a diverse population of critically ill patients in US care settings.īlood glucose blood glucose monitoring blood sugar in intensive care unit critical care laboratory performance evaluation point of care testing. ![]() Clinical evaluation demonstrated high specificity and sensitivity, with low risk of potential insulin-dosing errors. Proportions of results within evaluation boundaries 1 and 2, respectively, were 96% and 98% for venous samples, 94% and 97% for pediatric and adult arterial samples, 84% and 98% for neonatal arterial samples, and 96% and 100% for neonatal heel-stick samples. AccuChek Inform II Competency Requirements PHSA. Highlights of New AccuChek Inform II Whole Blood Glucose System. ![]() Clinical performance was assessed by evaluating sample data using Parkes error grid, Monte Carlo simulation, and sensitivity and specificity analyses to estimate clinical accuracy and implications for insulin dosing when using the ACCU-CHEK Inform II system. Charging the AccuChek Inform II on the Base Unit. The ACCU-CHEK Inform II system was evaluated at 2 cutoff boundaries: boundary 1 was ≥95% of results within ☑2 mg/dL of the reference (samples with blood glucose <75 mg/dL) or ☑2% of the reference (glucose ≥75 mg/dL), and boundary 2 was ≥98% of results within ☑5 mg/dL or ☑5% of the reference. Overall, 476 arterial (376 pediatric/adult, 100 neonate), 375 venous, and 100 neonatal heel-stick whole-blood samples were collected and evaluated from critical care settings at 10 US hospitals, including the emergency department, medical and surgical intensive care units (ICUs), and neonatal and pediatric ICUs. Our purpose was to evaluate the performance of the ACCU-CHEK® Inform II blood glucose monitoring system (Roche Diagnostics GmbH) compared with the perchloric acid hexokinase (PCA-HK) comparator method on the cobas® 6000 analyzer (Roche Diagnostics International Ltd) in critically ill patients.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |